Media centre
ASA404 enters phase III trial
11/04/2008 - ASA404 enters phase III trial in lung cancer
Antisoma announces that its partner Novartis has started the pivotal phase III trial of ASA404 in non-small cell lung cancer (NSCLC). The study, called ATTRACT-1, is designed to support applications for marketing authorisations for ASA404 in the US, Europe and other territories.
Two webcasts/ conference calls will be held on Friday April 11
at 9:30am BST / 4:30am EST;
and at 2pm BST / 9am EST.
To access a recording of the webcasts and teleconferences:
| Friday April 11 9:30am BST / 4:30am EST |
Slide presentation with audio Q&A teleconference |
Back to top